LAVAL, Quebec, Sept. 27, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced that Paul S. Herendeen, executive vice president, Finance, and chief financial officer; Linda LaGorga, senior vice president, Finance, and treasurer; and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications; are scheduled to participate at the Deutsche Bank 25th Annual Leveraged Finance Conference in Scottsdale, Ariz. on Oct. 4, 2017 at 8:00 a.m. MST (11:00 a.m. EDT).
A live webcast and audio archive of the event will be available on the Investor Relations page of the Valeant web site at: http://ir.valeant.com/events-and-presentations/2017.
About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.
|
Investor Contact: |
Media Contact: |
|
Arthur Shannon |
Lainie Keller |
|
arthur.shannon@valeant.com |
lainie.keller@valeant.com |
|
(514) 856-3855 |
(908) 927-0617 |
|
(877) 281-6642 (toll free) |
SOURCE Valeant Pharmaceuticals International, Inc.